AR016604A1 - Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos - Google Patents

Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos

Info

Publication number
AR016604A1
AR016604A1 ARP980103977A ARP980103977A AR016604A1 AR 016604 A1 AR016604 A1 AR 016604A1 AR P980103977 A ARP980103977 A AR P980103977A AR P980103977 A ARP980103977 A AR P980103977A AR 016604 A1 AR016604 A1 AR 016604A1
Authority
AR
Argentina
Prior art keywords
compounds
vinyl
eteres
heterociclic
atom
Prior art date
Application number
ARP980103977A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR016604A1 publication Critical patent/AR016604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de compuestos derivados de éteres vinílicos heterocíclicos de formula general 1, en donde R significa halogeno o alquilo inferior; n significa 0-3; R1significa alquilo inferior; cicloalquilo; bencilo opcionalmente sustituido por hidroxi, halogeno, alcoxi inferior o alquilo inferior; benzoilo opcionalmentesustituido por amino, alquilamino inferior o dialquilamino inferior; acetilo o cicloalquilo-carbonilo; y el ciclo A significa un residuo aromático de 5miembros que está unido a través de unátomo de N y que contiene 1-3 átomos de N adicionales además del átomo N ligante que se usan para la produccion demedicamentos. Compuestos derivados de éteres vinílicos heterocícliocos de formula general I en donde R y R tienen los significados dadomás arriba y el cicloA significa un anillo aromático de 5 miembros que está unido a través de un átomo de N y que contiene 1 o 3 átomos de N adicionales además del átomo de Nligante. Un procedimiento para la elaboracion de estos compuestos derivadosy medicamentos que contienen uno o más compuestos de formula general I y unexcipiente terapéuticamente inerte. Algunos derivados de triazol que se encuentran comprendidos en la formula I se conocen desde hace mucho tiempo. El ácidoL-glutámico, el neurotransmisor presente más comunmente en el SNC, juega un papel crítico en un gran Ns de procesos fisiologicos. Este actua sobre losreceptores de estímulos específicos (glutamato-dependientes) mediante un mecanismo por el cual se pueden corregir trastornos como la enfermedad de Alzheimer,corea de Huntington, esclerosis lateral amiotrofica, demencia causada por SIDA y retinopatías. Se ha hallado sorprendentemente que los compuestos de la formulaI son antagonistas y/o agonistas de los receptores glutamato metabotropicos, por lo cual los mismos junto con sus sales farmacéuticamente aceptables comoterapéuticamente activas y medicamentos basados en dichos compuestos, constituyen un arma valiosa para el control o la prevencion de las enfermedadesarribamencionadas.
ARP980103977A 1997-08-14 1998-08-12 Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos AR016604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114065 1997-08-14

Publications (1)

Publication Number Publication Date
AR016604A1 true AR016604A1 (es) 2001-07-25

Family

ID=8227219

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103977A AR016604A1 (es) 1997-08-14 1998-08-12 Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos

Country Status (24)

Country Link
US (2) US6054588A (es)
EP (1) EP1003505B1 (es)
JP (1) JP3593031B2 (es)
KR (1) KR100357650B1 (es)
CN (1) CN1154489C (es)
AR (1) AR016604A1 (es)
AT (1) ATE262331T1 (es)
AU (1) AU741532B2 (es)
BR (1) BR9811933A (es)
CA (1) CA2297732C (es)
DE (1) DE69822638T2 (es)
ES (1) ES2216305T3 (es)
HR (1) HRP20000079A2 (es)
HU (1) HUP0004412A3 (es)
ID (1) ID28529A (es)
IL (1) IL134168A0 (es)
NO (1) NO20000738L (es)
NZ (1) NZ502463A (es)
PL (1) PL192029B1 (es)
RU (1) RU2218919C2 (es)
TR (1) TR200000405T2 (es)
WO (1) WO1999008678A1 (es)
YU (1) YU6100A (es)
ZA (1) ZA987145B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115871A (pt) 2000-12-04 2003-10-28 Hoffmann La Roche Derivados de feniletenila ou feniletinila como antagonistas de receptores de glutamato
JP2005502618A (ja) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション 光力学的化合物を用いて脆弱なプラークを検出および治療する方法
DE10205057A1 (de) * 2002-02-07 2003-08-14 Bayer Cropscience Ag Substituierte 4-Hetaryl-pyrazoline
WO2004078715A1 (ja) 2003-03-07 2004-09-16 Astellas Pharma Inc. ２，６－ジ置換スチリルを有する含窒素へテロ環誘導体
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
KR100907108B1 (ko) 2004-06-01 2009-07-09 에프. 호프만-라 로슈 아게 Ｍｇｌｕ5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸
ITVA20050050A1 (it) * 2005-08-05 2007-02-06 Lamberti Spa Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita'
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
LT2083811T (lt) 2006-11-22 2017-01-25 Clinical Research Associates, Llc Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PT2200985E (pt) 2007-09-14 2011-07-21 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN102506473B (zh) * 2011-10-18 2014-06-11 江苏七彩科技有限公司 直接蒸发式冰蓄冷制冷系统及其制冷方法
CN102690240B (zh) * 2012-06-07 2014-09-10 郑州大学 三氮唑烯醚类、肟醚类化合物及其制备方法与应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX2016009471A (es) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso.
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
CN106279038A (zh) * 2016-08-16 2017-01-04 湖南中威制药有限公司 一种硝酸奥昔康唑原料药的合成方法
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
AU2017374458B2 (en) * 2016-12-14 2023-03-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
KR20230066244A (ko) 2021-11-06 2023-05-15 김경민 점선식 포장지

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330545A (en) 1977-02-21 1982-05-18 Siegfried Aktiengesellschaft Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or bactericides
DE2839388A1 (de) 1978-09-11 1980-03-27 Siegfried Ag Imidazolylvinylaether und deren verwendung
CH648552A5 (de) * 1981-01-23 1985-03-29 Siegfried Ag Verfahren zur herstellung von imidazolylvinylethern.
EP0079856A1 (de) * 1981-11-12 1983-05-25 Ciba-Geigy Ag Mikrobizide Triazolyl-vinyläther
DE3417468A1 (de) * 1984-05-11 1985-11-14 Bayer Ag, 5090 Leverkusen Azolylvinylether
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists

Also Published As

Publication number Publication date
AU741532B2 (en) 2001-12-06
IL134168A0 (en) 2001-04-30
HUP0004412A2 (hu) 2001-07-30
ATE262331T1 (de) 2004-04-15
KR100357650B1 (ko) 2002-10-25
NO20000738D0 (no) 2000-02-14
PL338637A1 (en) 2000-11-06
PL192029B1 (pl) 2006-08-31
HRP20000079A2 (en) 2000-12-31
US6248901B1 (en) 2001-06-19
ZA987145B (en) 1999-02-15
EP1003505B1 (en) 2004-03-24
ES2216305T3 (es) 2004-10-16
NO20000738L (no) 2000-04-11
DE69822638D1 (de) 2004-04-29
NZ502463A (en) 2002-05-31
YU6100A (sh) 2002-10-18
CA2297732C (en) 2008-04-29
CN1266368A (zh) 2000-09-13
AU9159398A (en) 1999-03-08
TR200000405T2 (tr) 2000-08-21
WO1999008678A1 (en) 1999-02-25
JP2001515037A (ja) 2001-09-18
KR20010022877A (ko) 2001-03-26
RU2218919C2 (ru) 2003-12-20
ID28529A (id) 2001-05-31
CN1154489C (zh) 2004-06-23
DE69822638T2 (de) 2005-02-24
BR9811933A (pt) 2000-09-05
US6054588A (en) 2000-04-25
HUP0004412A3 (en) 2003-06-30
EP1003505A1 (en) 2000-05-31
CA2297732A1 (en) 1999-02-25
JP3593031B2 (ja) 2004-11-24

Similar Documents

Publication Publication Date Title
AR016604A1 (es) Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
WO2000021927A3 (en) Pyrrole-2,5-diones as gsk-3 inhibitors
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
DE69426331T2 (de) Arzneimittel gegen nervöse erkrankungen
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ECSP024399A (es) Derivados de benzotiazol
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR004708A1 (es) Un derivado de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona, un medicamento, una composicion farmaceutica que lo comprende y un procedimiento de preparacion de dicho derivado.
HUT51637A (en) Process for producing heterocyclic derivatives of biphosphonic acid
ES2155535T3 (es) Inhibidores de sintesis de apoliproteina b.
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
MX9304524A (es) Nuevos derivados de indol y composiciones que los contienen.
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DE69500673T2 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
EP1238970A4 (en) CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
KR950032171A (ko) 옥소피리디닐퀴녹살린 유도체
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
EP1613328B8 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
FR2630110B1 (fr) Nouveaux derives heteroarotinoides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal